ET Capital, a seasoned investor in high-growth technology, has announced the launch of its Cambridge Venture Index SEIS/EIS Fund 2 (CVIF2). This new fund aims to support up to 20 early-stage, science-based companies emerging from the prestigious Cambridge and Oxford startup ecosystems. The initiative follows the successful close of its predecessor, CVIF1, expanding the firm's innovative approach to venture investment.
Expanding on a Successful Model
The launch of CVIF2 marks a significant expansion of ET Capital's mission to improve access to early-stage venture opportunities for angel investors. Building on the foundation of its first fund raised in 2025, which backed ten Cambridge companies, this new vehicle doubles the potential portfolio size. This growth reflects confidence in the firm's unique investment model and the rich pipeline of innovation from the two university clusters.
The first fund, CVIF1, has already demonstrated its potential by investing in promising ventures from Cambridge's leading accelerator programs. Portfolio companies include Reo Tx, which is developing advanced technology for a disease with significant unmet medical needs. Another notable investment is Cellestial Health, a biopharmaceutical company working to transform therapies for neurodegenerative diseases like Parkinson’s.
A Data-Driven Investment Strategy
At the core of ET Capital's approach is a structured venture investment technique designed to deliver diversified, risk-limited returns. This strategy is based on extensive proprietary research that analyzed the financing history of nearly 200 startups in the Cambridge cluster. The firm's model provides a compelling alternative to the traditional venture capital methodology of attempting to pick individual winners from a large pool.
The historical analysis, which modeled the performance of synthetic venture funds from 1992 to 2024, yielded impressive results. Using consistent criteria, five of the six synthetic funds outperformed the FTSE 100 Index, validating the index-based approach. By focusing on diversification, ET Capital aims to reduce the volatility often associated with early-stage investing and build more balanced portfolios for its clients.
Unlocking High-Potential Ecosystems
Martin Rigby, managing director of ET Capital, highlighted the exceptional quality of businesses emerging from the Cambridge and Oxford science clusters. He noted that these hubs produce some of the UK’s most groundbreaking deep science and technology startups. The new fund is designed to bridge the gap between these innovative companies and the sophisticated investors eager to support them.
The combined economic impact of the Cambridge and Oxford clusters is nearly £30 billion annually, driven by university research and associated spin-out companies. CVIF2 provides a direct channel for high-net-worth individuals to participate in the success of these world-leading technology hubs. The fund offers access to a broad range of deals that might otherwise be inaccessible, balancing significant potential with managed risk.
Investor and Founder Perspectives
The model has earned praise from the investment community, with Struan McDougall of Cambridge Capital Group expressing his support. As an investor in the first fund, he emphasized that the ecosystems produce an exciting wave of innovation but that opportunities are often limited. He sees ET Capital's approach as a vital way for a wider range of investors to back ventures with significant potential.
The sentiment is shared by founders within the ecosystem, such as Dr. Nat Hastings, CEO of portfolio company Cellestial Health. He stressed that innovative businesses require investors who provide not only capital but also valuable networks and a shared vision. ET Capital's venture index approach delivers this comprehensive support, enabling companies to advance their research and development for patient benefit.
The launch of the Cambridge Venture Index Fund 2 signifies a key development for both investors and early-stage science companies in the UK. By expanding its data-driven, diversified investment model, ET Capital is creating a more accessible and risk-managed pathway to support high-potential startups. This initiative is poised to fuel further innovation within Europe's leading technology clusters while offering a unique opportunity for sophisticated investors.